Edgewise Therapeutics has unveiled impressive results from EDG-7500, a novel treatment for the heart condition, obstructive hypertrophic cardiomyopathy (oHCM), with early safety and efficacy data exceeding expectations.
Edgewise’s Early Cardiomyopathy Data Builds Case For A Blockbuster
The EDG-7500 results have seen the company’s share price rocket, thanks to a potential advantage over existing treatments for the rare heart condition hypertrophic cardiomyopathy.
